**Alqahtani 2016** Alqahtani S, Kaddoumi A. Development of a Physiologically Based Pharmacokinetic/Pharmacodynamic Model to Predict the Impact of Genetic Polymorphisms on the Pharmacokinetics and Pharmacodynamics Represented by Receptor/Transporter Occupancy of Central Nervous System Drugs. Clinical Pharmacokinetics. 2016 Aug;55(8):957–69.

**Britz 2018** Britz H, Hanke N, Lehr T. Physiologically-based pharmacokinetic (PBPK) modeling of the strong CYP1A2 inhibitor fluvoxamine. PAGE meeting, Montreux, June 2018.

**Carillo 1996** Carrillo JA, Dahl ML, Svensson JO, Alm C, Rodríguez I, Bertilsson L.
Disposition of fluvoxamine in humans is determined by the polymorphic
CYP2D6 and also by the CYP1A2 activity. Clin Pharmacol Ther. 1996
Aug;60(2):183-90  

**DeVries 1993** De Vries MH, Van Harten J, Van Bemmel P, Raghoebar M. Pharmacokinetics of fluvoxamine maleate after increasing single oral doses in healthy subjects. Biopharmaceutics & Drug Disposition. 1993 May;14(4):291--6.

**DrugBank DB00176** (https://www.drugbank.ca/drugs/DB00176)

**FDA_ClinPharmReview LuvoxCR** FDA\_ClinPharmReview LuvoxCR, NDA 22-033, FDADrug\_42.pdf, website: digitalcollections.ohsu.edu/downloads/6m311p63g?locale=en

**FDA DDI Labeling** U.S. Food and Drug Administration. Drug development and drug interactions: table of substrates, inhibitors and inducers. \<Website fda.gov/Drugs/DevelopmentApprovalProcess/DevelopmentResources/DrugInteractionsLabeling/ucm093664.html (2017). Accessed 04 March 2019.

**Fleishaker 1994** Fleishaker JC, Hulst LK. A pharmacokinetic and pharmacodynamic evaluation of the combined administration of alprazolam and fluvoxamine. European Journal of Clinical Pharmacology. 1994;46(1):35--9.

**Fukasawa 2006** Fukasawa T, Yasui-Furukori N, Suzuki A, et al. Effects of Caffeine on the Kinetics of Fluvoxamine and its Major Metabolite in Plasma After a Single Oral Dose of the Drug. Ther Drug Monit. 2006;28(3):308-311.

**Iga 2015** Iga K. Use of Three-Compartment Physiologically Based Pharmacokinetic Modeling to Predict Hepatic Blood Levels of Fluvoxamine Relevant for Drug-Drug Interactions. J Pharm Sci. 2015;104(4):1478-1491.

**Iga 2016** Iga K. Dynamic and Static Simulations of Fluvoxamine-Perpetrated Drug-Drug Interactions Using Multiple Cytochrome P450 Inhibition Modeling, and Determination of Perpetrator-Specific CYP Isoform Inhibition Constants and Fractional CYP Isoform Contributions to Vic. *J Pharm Sci*.Victim Clearance. Journal of Pharmaceutical Sciences. 2016 Mar;105(3):1307-1317–17.

**Kuepfer 2016** Kuepfer L, Niederalt C, Wendl T, Schlender JF, Willmann S, Lippert J, Block M, Eissing T, Teutonico D. Applied Concepts in PBPK Modeling: How to Build a PBPK/PD Model.CPT Pharmacometrics Syst Pharmacol. 2016 Oct;5(10):516-531.

**Kunii 2005** Kunii T, Fukasawa T, Yasui-Furukori N, et al. Interaction Study Between Enoxacin and Fluvoxamine. Ther Drug Monit. 2005;27(3):349-353.

**Labellarte 2004** Labellarte M, Biederman J, Emslie G, et al. Multiple-dose pharmacokinetics of fluvoxamine in children and adolescents. J Am Acad Child Adolesc Psychiatry. 2004;43(12):1497-1505

**Lam 2003** Lam YWF, Alfaro CL, Ereshefsky L, Miller M. Pharmacokinetic and pharmacodynamic interactions of oral midazolam with ketoconazole, fluoxetine, fluvoxamine, and nefazodone. *J Clin Pharmacol*. 2003;43(11):1274-1282.

**Orlando 2009** Orlando R, De Martin S, Andrighetto L, Floreani M, Palatini P. Fluvoxamine pharmacokinetics in healthy elderly subjects and elderly patients with chronic heart failure. Br J Clin Pharmacol. 20 0 Mar;69(3):279-86.

**Perucca 1994** Perucca E, Gatti G, Spina E. Clinical Pharmacokinetics of Fluvoxamine: *Clinical Pharmacokinetics*. 1994 Sep;27(3):175--90.

**PK-Sim Ontogeny Database Version 7.3** (https://github.com/Open-Systems-Pharmacology/OSPSuite.Documentation/blob/38cf71b384cfc25cfa0ce4d2f3addfd32757e13b/PK-Sim%20Ontogeny%20Database%20Version%207.3.pdf)

**PubChem 9560989** (https://pubchem.ncbi.nlm.nih.gov/compound/9560989)

**Spigset 1997** Spigset O, Granberg K, Hägg S, Norström A, Dahlqvist R. Relationship between fluvoxamine pharmacokinetics and CYP2D6/CYP2C19 phenotype polymorphisms. Eur J Clin Pharmacol. 1997;52(2):129-33.

**Spigset 1998** Spigset O, Hägg S, Dahlqvist R, Granberg K, Söderström E. Non-linear fluvoxamine disposition. Br J Clin Pharmacol. 1998;45(3):257-263.

**NCT02853136** Influence of fluvoxamine on the pharmacokinetics of BI 409306 after oral administration (randomized, open-label, two-treatment, two-sequence, two-period crossover study)

**VanHarten 1991** Van Harten J, Van Bemmel P, Dobrinska MR, Ferguson RK, Raghoebar M. Bioavailability of fluvoxamine given with and without food. Biopharm Drug Dispos. 1991;12(8):571-576.

**VanHarten 1994** Van Harten J, Kok F, A. Lönnebo A. Grahnén A. Pharmacokinetics of fluvoxamine after intravenous and oral administration. Poster. P-1-58. 1994;4(3):331.

**Willmann 2007** Willmann S, Höhn K, Edginton A, Sevestre M, Solodenko J, Weiss W, Lippert J, Schmitt W. Development of a physiology-based whole-body population model for assessing the influence of individual variability on the pharmacokinetics of drugs. *J Pharmacokinet Pharmacodyn* 2007, 34(3): 401-431.
